Cerezyme market seen growing through 2030 as rare disease treatment expands

The Cerezyme market is projected to build on steady demand through the next decade as Gaucher disease diagnosis, reimbursement, and home infusion care improve. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Cerezyme targets Gaucher disease, a rare genetic disorder with limited treatment options, so market growth is closely tied to rare-disease diagnosis and access to specialty care. - Wider reimbursement, better biologic manufacturing, and more home-based infusion care could make enzyme replacement therapy easier to deliver. - The market outlook extends through 2035, with demand shaped by orphan-drug support and broader healthcare investment.

What happened: - The Business Research Company published its Cerezyme Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Cerezyme market has grown steadily on the back of limited alternatives for Gaucher disease, stronger diagnostics for rare disease, early use in specialty clinics, and orphan-drug incentives. - The report highlights a sample download and full report access for readers seeking the market data. - The report names North America as the largest regional market in 2025. - The report expects Asia-Pacific to be the fastest-growing region during the forecast period.

The details: - Cerezyme is an enzyme replacement therapy used to treat Gaucher disease, which is caused by a deficiency in glucocerebrosidase. - The therapy helps manage spleen and liver enlargement, anemia, low platelet counts, and bone problems by replacing the missing enzyme. - The treatment reduces fatty substance buildup in organs and tissues, which helps lower complications and improve patient health. - Rising R&D spending is identified as a key growth driver because it supports improvements in enzyme replacement therapies and broader therapeutic use. - The report cites the G-FINDER 2024 report, which showed global hepatitis C research funding rose by $5 million, or 30%, in 2023 to $21 million. - Expanding healthcare infrastructure is another driver because it supports the systems needed to administer enzyme replacement therapy. - The report cites American Medical Association data showing U.S. health spending rose 7.5% in 2023 to $4.9 trillion, or about $14,570 per person. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The report also adds key technology and future trend analysis. - A free sample is available here. - The full report is available here.

Between the lines: - The report points to a market that depends less on mass demand and more on deeper diagnosis, specialist access, and long-term disease management. - North America’s lead suggests mature reimbursement and treatment infrastructure already support uptake. - Asia-Pacific’s expected growth signals where future expansion may come from as healthcare capacity improves and rare-disease recognition rises.

What's next: - The market’s trajectory will depend on whether rare-disease awareness, reimbursement coverage, and home infusion options continue to expand. - Biologic manufacturing gains and orphan-drug incentives could further support adoption through 2035. - The Business Research Company is positioning the report as a planning tool for companies tracking regional demand and rare-disease treatment trends.

The bottom line: - Cerezyme remains a niche therapy, but the report sees a clear growth path as rare disease care becomes more accessible and more widely diagnosed.